Corcept Therapeutics (NASDAQ:CORT) Hits New 52-Week High - Still a Buy?

Key Points

• Corcept Therapeutics reached a new 52-week high of $122.88, supported by strong quarterly results: EPS of $0.36 beat estimates by $0.34, while revenue grew 31.7% year over year to $256.15 million.
• Analyst sentiment is broadly positive, with a “Moderate Buy” consensus and an average price target of $138.17; several firms set targets between $150 and $165 following raised earnings forecasts.
• Valuation and insider selling remain key risks. The stock trades at roughly 293 times earnings near its peak, while insiders have sold more than 520,000 shares worth approximately $48.9 million over the past 90 days.

Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report)'s stock price hit a new 52-week high during trading on Friday . The company traded as high as $122.88 and last traded at $122.62, with a volume of 19267 shares trading hands. The stock had previously closed at $121.05.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Zacks Research raised multiple EPS estimates. Forecasts increased for FY2026 to $1.02 from $0.38, FY2027 to $1.91 from $1.25, and FY2028 to $4.07 from $3.14. Quarterly estimates were also lifted, including Q1 2027 from a $0.17 loss to $0.11 profit and Q2 2028 from $0.69 to $1.17. These revisions suggest improving expectations for Corcept’s earnings trajectory, although Zacks continues to rate the shares “Hold.”
• Positive Sentiment: Recent operating results and growth commentary remain supportive. Corcept’s latest quarterly report showed EPS of $0.36 versus the $0.02 consensus estimate, while revenue rose 31.7% year over year to $256.15 million. An optimistic research article cited strong potential from Lifyorli’s launch in platinum-resistant ovarian cancer and continued Korlym growth, projecting revenue growth above 44% and substantial margin expansion. Like The Knicks, Corcept Rebounded And Is Crushing It
• Positive Sentiment: Wall Street price targets remain above the current trading level. Recent coverage includes Buy or equivalent ratings from Truist, Piper Sandler, HC Wainwright and Canaccord Genuity, with targets ranging from $150 to $165. The reported consensus target is $138.17, supporting the bullish momentum.
• Neutral Sentiment: Valuation is a risk consideration. Corcept’s market capitalization is approximately $13.1 billion and its P/E ratio is about 288, meaning investors are already paying a substantial premium for expected future growth. The shares are also near their 52-week high, which could increase sensitivity to disappointing results.
• Negative Sentiment: A director sold a sizable stake. Director David Mahoney sold 103,606 shares for approximately $12.25 million, reducing his ownership by 8.37%. He still owns more than 1.13 million shares, but the transaction may weigh on sentiment by signaling some profit-taking at elevated prices. Insider Selling: Corcept Therapeutics Director Sells Stock

Analyst Ratings Changes

A number of equities analysts have recently weighed in on CORT shares. Zacks Research raised Corcept Therapeutics from a "strong sell" rating to a "hold" rating in a report on Monday, May 4th. Wolfe Research lowered Corcept Therapeutics from a "peer perform" rating to an "underperform" rating and set a $50.00 price objective on the stock. in a research note on Monday, July 27th. UBS Group set a $135.00 price objective on Corcept Therapeutics in a research report on Thursday, May 28th. Wall Street Zen upgraded shares of Corcept Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 1st. Finally, HC Wainwright raised their price target on shares of Corcept Therapeutics from $95.00 to $165.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $138.17.

Corcept Therapeutics Trading Up 1.7%

The business has a 50 day simple moving average of $96.60 and a two-hundred day simple moving average of $64.19. The company has a market cap of $13.30 billion, a PE ratio of 293.05 and a beta of 0.45.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.02 by $0.34. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The firm had revenue of $256.15 million during the quarter, compared to analyst estimates of $221.15 million. During the same period in the prior year, the firm posted $0.29 earnings per share. The business's quarterly revenue was up 31.7% compared to the same quarter last year. On average, equities research analysts expect that Corcept Therapeutics Incorporated will post 1.61 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Joseph Douglas Lyon sold 1,540 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $114.16, for a total transaction of $175,806.40. Following the transaction, the insider directly owned 5,495 shares in the company, valued at $627,309.20. This represents a 21.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Sean Maduck sold 3,664 shares of the firm's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $114.49, for a total transaction of $419,491.36. Following the completion of the sale, the insider directly owned 9,755 shares in the company, valued at $1,116,849.95. This represents a 27.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 520,146 shares of company stock worth $48,903,764 over the last ninety days. Insiders own 20.70% of the company's stock.

Hedge Funds Weigh In On Corcept Therapeutics

A number of large investors have recently bought and sold shares of the stock. Alberta Investment Management Corp purchased a new stake in shares of Corcept Therapeutics during the second quarter valued at approximately $9,843,000. Avidity Partners Management LP acquired a new position in shares of Corcept Therapeutics during the fourth quarter worth $766,000. Norges Bank purchased a new position in shares of Corcept Therapeutics in the fourth quarter valued at $24,213,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Corcept Therapeutics in the fourth quarter valued at $8,757,000. Finally, BOKF NA acquired a new stake in Corcept Therapeutics during the 4th quarter valued at $1,061,000. Hedge funds and other institutional investors own 93.61% of the company's stock.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source